Encouragingly, some novel ideals point the direction for future drug development, such as inhibiting hypercholesterolemia in NS, targeting the AhR-STUB1-TF axis in CKD, and targeting FXI in dialysis. Here, AHR is linked to familial hypercholesterolemia.